Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Read more
Sun Pharma acquires Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio Read more
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers Read more
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar Read more
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Read more
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease Read more
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor Read more